Firms will offer integrated solutions for multiparticulate oral controlled-release products.
Drug formulation and delivery specialists Bend Research and Catalent Pharma Solutions inked an agreement to pool their expertise and offer integrated solutions for the development and manufacture of specialized multiparticulate oral controlled-release products. The firms are instigating joint operations and technology transfer protocols to provide a more seamless process for clients.
Bend Research offers an integrated pharmaceutical development services and solutions founded on expertise in formulation science, dosage form development, process development and engineering, cGMP production, biotherapeutics, and analytics. Catalent specializes in drug and biologics development services, drug delivery technologies including oral, injectable, and respiratory dosage forms, and supply solutions.
Commenting on the Bend-Catalent partnership, Bend CEO Rod Ray said the firms’ combined expertise will facilitate the efficient development of complex, multiparticulate controlled-release products, “which traditionally have presented a high scale-up risk when they are transferred to commercial manufacturing sites.”